Go Capital et al. invest in Pherecydes Pharma

New backers include Omnes Capital, Fa Dièse and a group of angel investors based in the Rhône-Alpes region.

Go Capital used its Ouest Ventures Fund III for the transaction. The VC's fund typically invests between €500,000-4m in French companies that operate in the digital economy, healthcare, food, biotechnology, environmental technology, materials sciences and nanotechnology sectors, according to unquote" data.

The new round of funding will enable the company to bring two programmes into clinical trials and to develop a pharmaceutical production unit in Nantes.

Previous funding
In 2015, Ace and Auriga took part in a €2.6m funding round for Pherecydes. The healthcare deal marked a departure for Ace, which tends to focus on sectors such as aerospace, transportation and defence.

Company
Founded in 2007, Pherecydes is developing a range of treatments for bacterial infections. Rather than focusing on antibiotics, the company is basing its products on phagotherapy – the therapeutic use of bacteriophages, natural bodies that feed off bacteria. The company has developed a bank of bacteriophage cocktails for the control of antibiotic-resistant infections. Pherecydes is based in Romainville.

People
Go Capital – Leila Nicolas (investment director).
Ace Management – Delphine Dinard (investment director)
Pherecydes Pharma – Guy-Charles Fanneau de La Horie (CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• France
• Healthcare
• France
• Omnes Capital
• ACE Management
• Venture